Gut Liver.  2017 Jan;11(1):79-86. 10.5009/gnl15585.

Helicobacter pylori Eradication Downregulates Cellular Inhibitor of Apoptosis Protein 2 in Gastric Carcinogenesis

• Yoon H
• Kim SG
• Kim BK
• Shin E
• Kim N
• Lee HJ
• Kang GH
• Jung HC

• KMID: 2412158
• DOI: http://doi.org/10.5009/gnl15585

Abstract

BACKGROUND/AIMS
To evaluate the expression of cellular inhibitor of apoptosis protein 2 (cIAP2) during gastric carcinogenesis after Helicobacter pylori (HP) infection and after HP eradication.
METHODS
We divided non-cancer patients into four groups according to the status of HP infection and atrophic gastritis (AG)/intestinal metaplasia (IM). We compared cIAP2 mRNA expression among these four groups and patients with HP-positive early gastric cancer (EGC) by using real-time polymerase chain reaction (PCR). We evaluated the expression of cIAP2 messenger RNA (mRNA)/protein by using real-time PCR/immunohistochemistry and the degree of apoptosis with a terminal deoxynucleotidyl transferase-mediated nick end labeling assay before and 12 months after endoscopic submucosal dissection (ESD) in HP-positive EGC patients, regardless of whether they had undergone eradication therapy.
RESULTS
The expression of cIAP2 mRNA was significantly higher in the groups with HP(+), AG/IM(+), and HP-positive EGC than in the control, HP(+), and AG/IM(−) groups (p<0.005). In the HP eradication group, the expression of cIAP2 mRNA/protein significantly decreased (p=0.006) and apoptosis increased at the 12-month follow-up after ESD. In the HP noneradication group, the aforementioned changes were not found during the same follow-up period.
CONCLUSIONS
The expression of cIAP2 increased during gastric carcinogenesis after HP infection; HP eradication in the patients who had undergone ESD for EGC reversed overexpression of cIAP2 and suppressed cell apoptosis.

Keyword

Helicobacter pylori; Cellular inhibitor of apoptosis protein 2; Gastric carcinogenesis

MeSH Terms

Amoxicillin/therapeutic use
Anti-Bacterial Agents/therapeutic use
Apoptosis/*genetics
Baculoviral IAP Repeat-Containing 3 Protein
Carcinogenesis/*genetics
Carcinoma/complications/*genetics/pathology/surgery
Clarithromycin/therapeutic use
Down-Regulation
Endoscopic Mucosal Resection
Gastritis, Atrophic/complications/*genetics/metabolism/pathology
Helicobacter Infections/complications/drug therapy/*genetics/metabolism
Helicobacter pylori
Humans
Immunohistochemistry
In Situ Nick-End Labeling
Inhibitor of Apoptosis Proteins/*genetics/metabolism
Metaplasia
Neoplasm Staging
Omeprazole/therapeutic use
Proton Pump Inhibitors/therapeutic use
RNA, Messenger/*metabolism
Real-Time Polymerase Chain Reaction
Stomach/pathology
Stomach Neoplasms/complications/*genetics/pathology/surgery
Ubiquitin-Protein Ligases/*genetics/metabolism
Anti-Bacterial Agents
Inhibitor of Apoptosis Proteins
Proton Pump Inhibitors
RNA, Messenger
Amoxicillin
Baculoviral IAP Repeat-Containing 3 Protein
Ubiquitin-Protein Ligases
Clarithromycin
Omeprazole